With the largest real-world sample to date (n = 3015), the results from ASTRIS support the clinical benefits of osimertinib in pretreated patients with EGFR T790M-positive advanced NSCLC without any new safety signals of concern. Here, EGFR is linked to non-small cell lung carcinoma.